AB SCIENCE |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.95 EUR | -1.12% |
|
-7.80% | -45.15% |
| May. 30 | Transcript : AB Science S.A. - Special Call | |
| May. 29 | AB Science: towards a negative opinion from the CHMP, listing suspended | CF |
ETFs positioned on AB Science
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 10 M€ | -3.35% | - |
AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.
Sector
Pharmaceuticals
Calendar
2024-09-29
- Q2 2024 Earnings Release
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.95
EUR
Average target price
6.895
EUR
Spread / Average Target
+253.59%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -45.15% | 110M | |
| +15.54% | 78.51B | |
| +12.05% | 9B | |
| +58.17% | 4.96B | |
| -14.94% | 4.84B | |
| -.--% | 3.72B | |
| +21.94% | 2.48B | |
| -26.63% | 2.19B | |
| +16.75% | 2.12B | |
| -37.97% | 1.94B |
- Stock Market
- Equities
- AB Stock
- Funds and ETFs AB Science
